Wikisage, the free encyclopedia of the second generation, is digital heritage
Fabry disease: Difference between revisions
Jump to navigation
Jump to search
(1-deoxygalactonojirimycin) |
(l) |
||
Line 4: | Line 4: | ||
[[migalastat]] or 1-deoxygalactonojirimycin received an orphan drug approval | [[migalastat]] or 1-deoxygalactonojirimycin received an orphan drug approval | ||
<ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616598.htm</ref> | <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616598.htm</ref> | ||
[https://www.ncbi.nlm.nih.gov/pubmed/30064518 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY] | |||
<references/> | <references/> |
Revision as of 00:42, 11 August 2018
Fabry disease is a genetic condition involving lysosomal storage (E75.2)[1]
migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [2]